Mandate

VINGE ADVISES ON OPUS GROUP’S RIGHTS ISSUE

February 13, 2015

Vinge is advising Opus Group in connection with a rights issue of approximately SEK 150 million. The rights issue is conditional upon approval by the members at an extraordinary general meeting to be held on 10 March 2015. The board of directors will determine the terms and conditions governing the rights issue not later five days prior to the record day. A prospectus is expected to be published on 11 March 2015 and the subscription period is 17-31 March 2015.

Vinge’s team advising on the preparation of the prospectus and capital markets issues consists of responsible partner Anders Strid together with associates Daniel Lennartsson, Frida Bäckgren and Anna Hofling Johansson (tax).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025